Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
Katherine K CliftonAngelica Gutierrez-BarreraJunsheng MaRoland BassettJennifer LittonHenry KuererStacy MoulderConstance AlbarracinGabriel HortobagyiBanu ArunPublished in: Breast cancer research and treatment (2018)
Neoadjuvant versus adjuvant with standard anthracycline- and taxane-containing regimens results in similar disease-free survival and overall survival among patients with stage I and II triple-negative breast cancer regardless of BRCA status. Further studies are needed to evaluate whether similar results are observed with newer agents.